Skip to main content
Signal8

SeaStar Medical Holding Corp (ICUCW)

Sector: Surgical & Medical Instruments & Apparatus

Industry: Biotechnology

SeaStar Medical Holding Corporation logo

SeaStar Medical Holding Corporation

NASDAQ:ICUCWSub-class of ICUHealthcare
-20.59%$0.0108
CLOSED
Mkt Cap$57K
Float-
O/S5.26M
VOL14K sh
$ Vol$206
RVOL0.47×
Inst Own-
EarningsNov 12 · in 3d
Dilution
SeaStar Medical Holding Corporation logoNASDAQ:ICUCWClosed$0.0108-20.59%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 20260.01070.01360.01070.012275
Nov 5, 20260.01360.01360.01070.010870
Nov 4, 20260.01360.01360.01210.013629
Nov 3, 20260.01300.01300.01060.010614,372
Nov 2, 20260.01000.01370.01000.0136150,496
Oct 30, 20260.01250.01250.01090.0109140,859
Oct 29, 20260.01270.01530.01270.014838
Oct 28, 20260.01520.01690.01210.0167198,098
Oct 27, 20260.01530.01530.01520.01534,377
Oct 26, 20260.01550.01560.01510.015520,620
Oct 23, 20260.01900.01900.01560.0156440
Oct 22, 20260.02000.02000.02000.0200102
Oct 21, 20260.02480.02490.02010.02023,100
Oct 20, 20260.02490.02490.02000.02012,759
Oct 19, 20260.01540.01990.01520.0152161
Oct 16, 20260.01490.01820.01490.014929
Oct 14, 20260.02020.02020.02000.020010,485
Oct 13, 20260.01560.01830.01560.015620,027
Oct 12, 20260.01760.01770.01540.017318,157
Oct 9, 20260.01530.01570.01520.015247
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(14)
--
Insiderⓘ
(0)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources: 13F
Insiders & Institutional Holders

Top institutional holders

About

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals.

The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions.

Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome.

The firm maintains its headquarters in Denver, Colorado.

Key Metrics
Market Cap$56,817
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 5.26M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateMar 18, 2021
Shares Outstanding5.26M
Authorized Shares
Float-
52-Week Range
$0.0084$0.0750
$0.0108(4th percentile)
Volume
Average Daily Volume30.75K
14.37K today vs 30.75K avg(-53%)

30d Avg

30.75K

60d Avg

31.91K

90d Avg

25.42K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...